Prostate cancer remains the most common type of cancer among men in the United States.
Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
Written by:
Zobniw CM, Causebrook A, Fong MK. Are you the author?
Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY, USA; School of Pharmacy, Lake Erie College of Osteopathic Medicine, Erie, PA, USA.
Reference: Res Rep Urol. 2014 Aug 5;6:97-105.
doi: 10.2147/RRU.S29003
PubMed Abstract
PMID: 25157341